The effect of topical application of royal jelly on
chemoradiotherapy-induced mucositis in head and neck cancer: a preliminary
study
Int J Otolaryngol. 2014;2014:974967
Purpose. One of the common side effects experienced by head
and neck cancer patients on chemoradiotherapy is mucositis. Severe mucositis
may be controllable by limiting cancer therapy, but it has resulted in
decreasing the completion rate of chemoradiotherapy. The efficacy of royal
jelly (RJ) as prophylaxis against chemoradiotherapy-induced mucositis was
evaluated through clinical scoring of oral and pharyngeal mucositis.
Methods. In this randomized, single-blind (physician-blind),
clinical trial, 13 patients with head and neck cancer requiring chemoradiation
were randomly assigned to two groups. Seven patients assigned to the study
group received RJ, and 6 patients were assigned to the control group. RJ group
patients took RJ three times per day during treatment. The patients in both
groups were evaluated twice a week for the development of mucositis using
Common Terminology Criteria for Adverse Events version 3.0.
Results. A significant reduction in mucositis was seen among
RJ-treated patients compared with controls (P < 0.001).
Conclusion. This study demonstrated that prophylactic use of
RJ was effective in reducing mucositis induced by chemoradiotherapy in head and
neck cancer patients. However, further studies are needed because of the small
sample size and the absence of double blinding.
No comments:
Post a Comment